Sfoglia per RIVISTA
IMMUNOTHERAPY
Collezione AO Ordine Mauriziano

  

Items : 7

Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab. in Immunotherapy / Immunotherapy. 2024;16(18-19):1095-1103. doi: 10.1080/1750743X.2024.2385881. Epub 2024 Aug 19.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Murianni V; Catalano F; Nolè F; Prati G; Morelli F; Messina M; Atzori F; Tudini M; Prati V; Roviello G; Cavo A; Vignani F; Caffo O; Napoli MD; Malgeri A; Rebuzzi SE; Signori A; Cremante M; Damassi A; Rescigno P; Banna GL; Fornarini G; Buti S;

Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis. in Immunotherapy / Immunotherapy. 2022 Feb;14(2):145-153. doi: 10.2217/imt-2021-0157. Epub 2021 Nov 22.

2022
AO Ordine Mauriziano

Brunelli M; Cattrini C; Mazzaschi G; Bersanelli M; Buti S; Di Maio M;

2022
AO Ordine Mauriziano

Procopio G; Losanno T; Naglieri E; Stellato M; Tambaro R; Banna GL; Vignani F; De Giorgi U; Basso U; Maruzzo M; Farè E; Raggi D; Giannatempo P; Mazzaschi G; Bersanelli M; Pignata S; Necchi A; Buti S;

Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study. in Immunotherapy / Immunotherapy. 2020 Feb;12(2):151-159. doi: 10.2217/imt-2019-0180.

2020
AO Ordine Mauriziano

Bersanelli M; Buti S; Banna GL; De Giorgi U; Cortellini A; Rebuzzi SE; Tiseo M; Fornarini G; Mazzoni F; Panni S; De Tursi M; Di Marino P; Rossetti S; Rossi E; Tomao S; De Luca E; Sorarù M; Mucciarini C; Atzori F; La Torre L; Vitale MG; Martelli V; Sepe P; Mollica V; Vaccaro V; Schinzari G; Ficorella C; Massari F; Maestri A; et alii...

Safety of uSCIT-MPL-4: prevalence and risk factors of systemic reactions in real life. in Immunotherapy / Immunotherapy. 2019 Jun;11(9):783-794. doi: 10.2217/imt-2019-0009. Epub 2019 May 16.

2019
AO Ordine Mauriziano

Caminati M; Arcolaci A; Guerriero M; Manzotti G; Crivellaro M; Rolla G; Fassio F; Senna G;

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study. in Immunotherapy / Immunotherapy. 2018 Oct;10(14):1229-1239. doi: 10.2217/imt-2018-0080.

2018
AO Ordine Mauriziano

Bersanelli M; Giannarelli D; Castrignanò P; Fornarini G; Panni S; Mazzoni F; Tiseo M; Rossetti S; Gambale E; Rossi E; Papa A; Cortellini A; Lolli C; Ratta R; Michiara M; Milella M; De Luca E; Sorarù M; Mucciarini C; Atzori F; Banna GL; La Torre L; Vitale MG; Massari F; Rebuzzi SE; Facchini G; Schinzari G; Tomao S; Bui S; et alii...

2018
AO Ordine Mauriziano

Circosta P; Vitaggio K; Elia AR; Todorovic M; Sangiolo D; Carnevale-Schianca F; Vallario A; Geuna M; Aglietta M; Cignetti A;